Ö÷³Ö£º£º£ºÄϹ¬NG28¼¯ÍÅ ÎâÃñ»ª¸±½ÌÊÚ

ʱ¼ä

±¨¸æÄÚÈÝ

±¨¸æר¼Ò

µ¥Î»

08£º£º£º30-08£º£º£º45

ÂÛ̳Ö÷ϯ»ÆÎÄ»ª½ÌÊÚÖ´Ç

08£º£º£º45-09£º£º£º30

³¤·Ç±àÂëRNAÓë賦µÀÖ×Áö

ÕÔ¡¡ÁÁ ½ÌÊÚ

ÄÏ·½Ò½¿Æ´óѧ

09£º£º£º30-10£º£º£º15

Roles of RNA Modification in Cancer Diagnosis and

Therapy

Íõºìʤ ½ÌÊÚ

ÖÐɽ´óѧ

10£º£º£º15-10£º£º£º25

Öг¡ÐÝÏ¢

10£º£º£º25-11£º£º£º10

È¥SUMO»¯ÂÑ°×ø1µÄÉúÎïѧ¹¦Ð§Ñо¿

×ó Ó Ñо¿Ô±

ÉϺ£½»Í¨´óѧ

11£º£º£º10-11£º£º£º55

ÇéÐλ¯Ñ§ÎïÖ²¡µÄ·Ç±àÂëRNA»úÖÆ

½¯Òå¹ú ½ÌÊÚ

¹ãÖÝÒ½¿Æ´óѧ

ÏÂÖ糡£¡£º£º£ºÑо¿ÉúÁ¢ÒìÂÛ̳£¬£¬£¬ÖÕ½áʽ

Ö÷³Ö£º£º£ºÄϹ¬NG28¼¯ÍÅ Ò¶Ïþϼ½ÌÊÚ¡¢¡¢¡¢ÒÂÑÞ÷¸±½ÌÊÚ

ʱ¼ä

ÄÚÈÝ

»ã±¨Õß

µãÆÀר¼Ò

13£º£º£º30-13£º£º£º50

Çâõ«ÓÕµ¼Ï¸°û¶ñÐÔת»¯Àú³ÌÖÐhsa_circ_0001944ͨ¹ýµ÷ÀíPARP1ʹϸ°ûÖÜÆÚÕÏ°­ºÍÓÕµ¼Ï¸°ûµòÍö

ÖÓ²®»¸

ÄϹ¬NG28¼¯ÍÅ

²Ì¿¡³¬ ½ÌÊÚ

ÖÐɽ´óѧ

13£º£º£º50-14£º£º£º10

ÒÈÏÙµ¼¹ÜÏÙ°©Ô¤ºóÏà¹ØµÄ×ÔÊÉlncRNA·çÏÕÆÀ·ÖµÄ¹¹½¨¼°ÆÊÎö

ÌÆÌïÊé

ÄϹ¬NG28¼¯ÍÅ

Öì ·å ½ÌÊÚ

Õã½­´óѧ

14£º£º£º10-14£º£º£º30

microRNA   ±ÇÇ»¸øÒ©Ô¤·À·ÅÉäÐÔÄÔËðÉ˵ÄÑо¿

²ÌÓñ½à

ÄϹ¬NG28¼¯ÍÅ

²Ì¿¡³¬ ½ÌÊÚ

ÖÐɽ´óѧ

14£º£º£º30-14£º£º£º50

¾²Ï¢¼°»î»¯ºóÊȼîÐÔÁ£Ï¸°ûȪԴÍâÃÚÌåȫת¼×éѧÆÊÎö

ÁÎÊçÕä

ÄϹ¬NG28¼¯ÍÅ

Öì ·å ½ÌÊÚ

Õã½­´óѧ

14£º£º£º50-15£º£º£º10

CircFOXO3Ó°ÏìѪ¹ÜÄÚƤϸ°ûÐàÂõµÄ×÷ÓûúÖƼ°ÆäÓë¹ÚÐIJ¡ÒÅ´«Ò׸еÄÏà¹ØÐÔÑо¿

ÖÜÓñÀ¼

ÄϹ¬NG28¼¯ÍÅ

²Ì¿¡³¬ ½ÌÊÚ

ÖÐɽ´óѧ

15£º£º£º10-15£º£º£º30

»ùÓÚÉúÎïÐÅϢѧÆÊÎöʳ¹Ü°©ÖÎÁƵÄDZÔڰлùÒò

Ðì ÄÈ

ÄϹ¬NG28¼¯ÍÅ

Öì ·å ½ÌÊÚ

Õã½­´óѧ

15£º£º£º30-15£º£º£º40

Öг¡ÐÝÏ¢

15£º£º£º40-16£º£º£º00

miRNA-296-5pͨ¹ýSTAT3½µµÍÖ×Áöϸ°û¸ÉÐÔÔö½ø±ÇÑÊ°©Ï¸°û¶Ô˳²¬Ãô¸ÐÐÔµÄʵÑéÑо¿

ÈÎ ¾²

ÄϹ¬NG28¼¯ÍÅ

Íò±ø±ø Ñо¿Ô±

ÉϺ£½»Í¨´óѧ

16£º£º£º00-16£º£º£º20

SIRT6°ÐÏòc-Jun¸ºÏòµ÷¿ØÖÜΧÉñ¾­ËðÉË»ªÀÕ±äÐÔºÍÊ©Íòϸ°ûÈ¥·Ö»¯

×Þ Ó±

ÄÏ·½Ò½¿Æ´óѧ

¹ù¼ÒËÉ ½ÌÊÚ

ÄÏ·½Ò½¿Æ´óѧ

16£º£º£º20-16£º£º£º40

»ùÓÚTXNIP½éµ¼µÄÏßÁ£ÌåÑõ»¯Á×Ëữ̽ÌÖGIO·¢²¡»úÖƼ°µ¤²ÎËصĸÉÔ¤×÷ÓÃ

½¶½¿

ÄϹ¬NG28¼¯ÍÅ

Íò±ø±ø Ñо¿Ô±

ÉϺ£½»Í¨´óѧ

16£º£º£º40-17£º£º£º00

IL-17A   accelerates demyelination through activating SOCS3 in astrocyte during A.   cantonensis infection

ÖÜ×ÚÆÓ

»ªÄÏÀí¹¤´óѧ

¹ù¼ÒËÉ ½ÌÊÚ

ÄÏ·½Ò½¿Æ´óѧ

17£º£º£º00-17£º£º£º20

°¢·¨ÌæÄáDZÔÚÄÍÒ©»ùÒòBIRC5ÔÚ·ÇСϸ°û·Î°©ÖеÄÅжÏÓëÑéÖ¤

ÖìСÜç

ôßÄÏ´óѧ

Íò±ø±ø Ñо¿Ô±

ÉϺ£½»Í¨´óѧ

17£º£º£º20-17£º£º£º40

The   potential regulatory role of TLR2 in the reducing inflammation by GV-EA   treatment in spinal cord injury

µËÇàÎÄ

ÖÐɽ´óѧ

¹ù¼ÒËÉ ½ÌÊÚ

ÄÏ·½Ò½¿Æ´óѧ

17£º£º£º40-17£º£º£º50

ÖÕ½á×ܽáÖ´Ç¡¢¡¢¡¢Ðû²¼ÆÀÓÅЧ¹û

ÌÆ»ÀÎÄ ½ÌÊÚ

ÄϹ¬NG28¼¯ÍÅ